SSTR5 receptors have been found in high density in functional [[Cushing's disease]] ACTH-PAs, and treatment with this agent reduces abnormal [[ACTH]] secretion and reduces tumor volume. Adverse effects include an increased risk of developing or worsening [[diabetes mellitus]] and the adverse gastrointestinal effects commonly seen with this class of drug.